ArticleCancer immunology, immunotherapy : CII2024

Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.

Yu-Ting Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.